Experienced in Sarcoidosis

Thierry Pieters

Brussels, BRU, BE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Sarcoidosis
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Thierry Pieters practices in Brussels, Belgium. Mr. Pieters is rated as an Experienced expert by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Acute Interstitial Pneumonia, and Interstitial Lung Disease.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Sarcoidosis.

Gender
Male

Locations

Brussels, BRU, Belgium
Other Locations
CHR de la Citadelle
Liege, WAL, Belgium
Antwerpen, VLG 2020, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
Census and Follow-up of the Side Effects in the New Immunotherapeutic Treatments Anti-PD-(L)-1 and Anti-CTLA-4 of the Non Small Cells Lung Cancer
Census and Follow-up of the Side Effects in the New Immunotherapeutic Treatments Anti-PD-(L)-1 and Anti-CTLA-4 of the Non Small Cells Lung Cancer
Enrollment Status: Completed
Publish Date: February 19, 2019
Intervention Type: Other
View 4 Less Clinical Trials

26 Total Publications

A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.
Journal: Acta oncologica (Stockholm, Sweden)
Published: May 16, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pieters's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile